CSPC Pharma Presents Results of Tumor Drug Studies at ESMO Congress 2026

MT Newswires Live
1 hour ago

CSPC Pharmaceutical Group (HKG:1093) presented results from two tumor drug studies as rapid oral presentations at the European Society for Medical Oncology Congress 2026, two Tuesday bourse filings showed.

Results from a phase I/II clinical study of SYS6090 showed a manageable safety profile and preliminary anti-tumor activity in patients with advanced solid tumors.

Results from another phase I/II trial of SYS6043 also demonstrated a manageable safety profile and favorable durable anti-tumor activity in previously-treated patients with advanced breast cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10